Prime Medicine, Inc.
PRME
$1.24
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.18M | 209.00K | -- | 591.00K | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.18M | 209.00K | -- | 591.00K | -- |
| Cost of Revenue | 34.10M | 40.34M | 43.07M | 37.77M | 41.46M |
| Gross Profit | -31.92M | -40.13M | -43.07M | -37.18M | -41.46M |
| SG&A Expenses | 12.30M | 14.10M | 12.60M | 11.16M | 13.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.41M | 54.44M | 55.67M | 48.93M | 54.54M |
| Operating Income | -44.22M | -54.23M | -55.67M | -48.34M | -54.54M |
| Income Before Tax | -42.28M | -52.52M | -55.46M | -45.63M | -65.64M |
| Income Tax Expenses | -- | -- | -134.00K | 134.00K | 0.00 |
| Earnings from Continuing Operations | -42.28M | -52.52M | -55.33M | -45.76M | -65.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.28M | -52.52M | -55.33M | -45.76M | -65.64M |
| EBIT | -44.22M | -54.23M | -55.67M | -48.34M | -54.54M |
| EBITDA | -42.51M | -52.67M | -54.13M | -47.03M | -53.30M |
| EPS Basic | -0.32 | -0.44 | -0.46 | -0.44 | -0.71 |
| Normalized Basic EPS | -0.20 | -0.28 | -0.29 | -0.28 | -0.36 |
| EPS Diluted | -0.32 | -0.44 | -0.46 | -0.44 | -0.71 |
| Normalized Diluted EPS | -0.20 | -0.28 | -0.29 | -0.28 | -0.36 |
| Average Basic Shares Outstanding | 130.92M | 119.76M | 119.19M | 104.47M | 92.47M |
| Average Diluted Shares Outstanding | 130.92M | 119.76M | 119.19M | 104.47M | 92.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |